

<b>Indication</b>	Adjuvant treatment of breast cancer
<b>Treatment Intent</b>	Adjuvant
<b>Frequency and number of cycles</b>	Every 21 days for 4 cycles
<b>Monitoring parameters pre-treatment</b>	<ul style="list-style-type: none"> <li>• ECG should be checked prior to cycle 1</li> <li>• Monitor FBC, LFT and U&amp;E at each cycle</li> <li>• If neuts &lt;1 or PLT &lt;100 d/w consultant</li> <li>• Impaired renal and liver function – d/w consultant</li> <li>• Dose reduction should be considered if grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&amp;V and alopecia). Delay until resolution of toxicity to &lt;= grade 1</li> <li>• Consider using actual BSA</li> <li>• NB For funding information, refer to the SACT funding spreadsheet</li> </ul>
<b>Reference(s)</b>	BRE-058 v1

Protocol No	BRE-058	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	2 FINAL	Written by	C Waters/P Williams
Supersedes version	1.0 FINAL	Checked by	K Miller
Date	05/06/18	Authorising consultant (usually NOG Chair)	C Abson

## Cycles 1-4 Repeat every 21 days

Day	Drug	Dose	Route	Infusion Duration	Administration Details
Day 1	Dexamethasone	8mg	PO		
	Ondansetron	<75yrs 16mg ≥75yrs 8mg	IVI	15 min	In 50ml Sodium chloride 0.9%
	<b>EPIRUBICIN</b>	90mg/m <sup>2</sup>	as a slow IV bolus		Through the side of a fast running 0.9% sodium chloride intravenous infusion
	<b>CYCLOPHOSPHAMIDE</b>	600mg/m <sup>2</sup>	as a slow IV bolus		Through the side of a fast running 0.9% sodium chloride intravenous infusion

TTO	Drug	Dose	Route	Directions
Day 1	Dexamethasone	6mg	PO	OM for 3 days
	Metoclopramide	10mg	PO	up to 3 times a day for 3 days, then 10mg up to 3 times a day as required. Do not take for more than 5 days continuously.
	Ondansetron	8mg	PO	BD for 3 days
	Filgrastim	5mcg/kg	Subcutaneous injection	Starting on day 5 for 5 days

Protocol No	BRE-058	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	2 FINAL	Written by	C Waters/P Williams
Supersedes version	1.0 FINAL	Checked by	K Miller
Date	05/06/18	Authorising consultant (usually NOG Chair)	C Abson